PortfoliosLab logoPortfoliosLab logo
EWTX vs. SPRY
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

EWTX vs. SPRY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Edgewise Therapeutics Inc (EWTX) and Silverback Therapeutics Inc (SPRY). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

EWTX vs. SPRY - Yearly Performance Comparison


2026 (YTD)20252024202320222021
EWTX
Edgewise Therapeutics Inc
26.94%-7.06%144.06%22.37%-41.49%-49.07%
SPRY
Silverback Therapeutics Inc
-31.07%10.43%92.52%-35.76%28.08%-85.92%

Fundamentals

Market Cap

EWTX:

$3.24B

SPRY:

$791.49M

EPS

EWTX:

-$1.61

SPRY:

-$1.74

PB Ratio

EWTX:

6.21

SPRY:

6.93

Total Revenue (TTM)

EWTX:

$0.00

SPRY:

$84.28M

Gross Profit (TTM)

EWTX:

$0.00

SPRY:

$45.85M

EBITDA (TTM)

EWTX:

-$191.41M

SPRY:

-$175.98M

Returns By Period

In the year-to-date period, EWTX achieves a 26.94% return, which is significantly higher than SPRY's -31.07% return.


EWTX

1D
4.03%
1M
3.48%
YTD
26.94%
6M
94.20%
1Y
43.18%
3Y*
67.78%
5Y*
0.97%
10Y*

SPRY

1D
2.75%
1M
-13.47%
YTD
-31.07%
6M
-20.10%
1Y
-36.17%
3Y*
7.25%
5Y*
-28.93%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Edgewise Therapeutics Inc

Silverback Therapeutics Inc

Return for Risk

EWTX vs. SPRY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EWTX
EWTX Risk / Return Rank: 6060
Overall Rank
EWTX Sharpe Ratio Rank: 6161
Sharpe Ratio Rank
EWTX Sortino Ratio Rank: 6363
Sortino Ratio Rank
EWTX Omega Ratio Rank: 6363
Omega Ratio Rank
EWTX Calmar Ratio Rank: 5858
Calmar Ratio Rank
EWTX Martin Ratio Rank: 5555
Martin Ratio Rank

SPRY
SPRY Risk / Return Rank: 2121
Overall Rank
SPRY Sharpe Ratio Rank: 1717
Sharpe Ratio Rank
SPRY Sortino Ratio Rank: 1919
Sortino Ratio Rank
SPRY Omega Ratio Rank: 2020
Omega Ratio Rank
SPRY Calmar Ratio Rank: 2323
Calmar Ratio Rank
SPRY Martin Ratio Rank: 2424
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EWTX vs. SPRY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Edgewise Therapeutics Inc (EWTX) and Silverback Therapeutics Inc (SPRY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


EWTXSPRYDifference

Sharpe ratio

Return per unit of total volatility

0.55

-0.54

+1.09

Sortino ratio

Return per unit of downside risk

1.30

-0.50

+1.80

Omega ratio

Gain probability vs. loss probability

1.18

0.94

+0.23

Calmar ratio

Return relative to maximum drawdown

0.74

-0.56

+1.30

Martin ratio

Return relative to average drawdown

1.31

-0.97

+2.28

EWTX vs. SPRY - Sharpe Ratio Comparison

The current EWTX Sharpe Ratio is 0.55, which is higher than the SPRY Sharpe Ratio of -0.54. The chart below compares the historical Sharpe Ratios of EWTX and SPRY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


EWTXSPRYDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.55

-0.54

+1.09

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.01

-0.36

+0.37

Sharpe Ratio (All Time)

Calculated using the full available price history

0.01

-0.24

+0.25

Correlation

The correlation between EWTX and SPRY is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

EWTX vs. SPRY - Dividend Comparison

Neither EWTX nor SPRY has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

EWTX vs. SPRY - Drawdown Comparison

The maximum EWTX drawdown since its inception was -84.69%, smaller than the maximum SPRY drawdown of -95.20%. Use the drawdown chart below to compare losses from any high point for EWTX and SPRY.


Loading graphics...

Drawdown Indicators


EWTXSPRYDifference

Max Drawdown

Largest peak-to-trough decline

-84.69%

-95.20%

+10.51%

Max Drawdown (1Y)

Largest decline over 1 year

-43.27%

-63.32%

+20.05%

Max Drawdown (5Y)

Largest decline over 5 years

-81.79%

-93.45%

+11.66%

Current Drawdown

Current decline from peak

-13.98%

-86.71%

+72.73%

Average Drawdown

Average peak-to-trough decline

-55.23%

-77.98%

+22.75%

Ulcer Index

Depth and duration of drawdowns from previous peaks

27.07%

36.73%

-9.66%

Volatility

EWTX vs. SPRY - Volatility Comparison

The current volatility for Edgewise Therapeutics Inc (EWTX) is 12.84%, while Silverback Therapeutics Inc (SPRY) has a volatility of 17.65%. This indicates that EWTX experiences smaller price fluctuations and is considered to be less risky than SPRY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


EWTXSPRYDifference

Volatility (1M)

Calculated over the trailing 1-month period

12.84%

17.65%

-4.81%

Volatility (6M)

Calculated over the trailing 6-month period

55.95%

51.95%

+4.00%

Volatility (1Y)

Calculated over the trailing 1-year period

78.84%

67.04%

+11.80%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

80.73%

80.53%

+0.20%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

81.37%

81.43%

-0.06%

Financials

EWTX vs. SPRY - Financials Comparison

This section allows you to compare key financial metrics between Edgewise Therapeutics Inc and Silverback Therapeutics Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober0
28.09M
(EWTX) Total Revenue
(SPRY) Total Revenue
Values in USD except per share items